NanoSphere Health Sciences Inc (TSE:NSHS)
:NSHS
Want to see TSE:NSHS full AI Analyst Report?
Top Page
NanoSphere Health Sciences Inc
(NSHS)
Select Model
Select Model
Rating:39Underperform
Price Target:
C$0.02
▼(-5.00% Downside)
Action:Downgraded
Date:05/07/26
The score is driven primarily by weak financial fundamentals (pre-revenue, persistent cash burn, and deeply negative equity) and a fragile capital structure. Technicals also detract due to a sustained downtrend and weak momentum, while valuation is limited by negative earnings and no dividend support.
Positive Factors
Narrowing cash burn
Narrowing cash burn reduces near-term funding pressure and extends operational runway, giving management more time to advance development milestones. This durable improvement lowers refinancing frequency and preserves strategic optionality for partnerships or staged financing.
Negative Factors
Pre-revenue company
No reported revenue indicates the company is pre-commercial, lacking product-market validation and recurring cash inflows. Structurally this creates long timelines to profitability, high execution risk, and persistent dependence on external capital to fund operations and trials.
Read all positive and negative factors
Positive Factors
Negative Factors
Narrowing cash burn
Narrowing cash burn reduces near-term funding pressure and extends operational runway, giving management more time to advance development milestones. This durable improvement lowers refinancing frequency and preserves strategic optionality for partnerships or staged financing.
Read all positive factors
NanoSphere Health Sciences Inc (NSHS) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$205.50K
Dividend YieldN/A
Average Volume (3M)9.76K
Price to Earnings (P/E)―
Beta (1Y)-3.55
Revenue GrowthN/A
EPS Growth-132.14%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding10,275,205
10 Day Avg. Volume800
30 Day Avg. Volume9,759
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.14
Price to Sales (P/S)0.00
P/FCF Ratio-8.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NanoSphere Health Sciences Inc Business Overview & Revenue Model
Company Description
NanoSphere Health Sciences Inc., a nano-biotechnology company, focuses on providing biologically active compounds in the United States and Canada. It offers NanoSphere Deliver System, a platform using nanotechnology in the bio delivery of suppleme...
NanoSphere Health Sciences Inc Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
6
Very Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -181.91K | 0.00 | 0.00 | -286.00K | -341.00K |
| Net Income | -86.27K | ― | -228.13K | -282.00K | -356.00K |
Balance Sheet | |||||
| Total Assets | 16.81K | 13.59K | 17.97K | 60.05K | 132.51K |
| Cash, Cash Equivalents and Short-Term Investments | 1.88K | 2.02K | 9.32K | 55.01K | 130.76K |
| Total Debt | 57.14K | 30.71K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.37M | 1.23M | 1.57M | 1.37M | 1.21M |
| Stockholders Equity | -1.35M | -1.22M | -1.56M | -1.31M | -1.08M |
Cash Flow | |||||
| Free Cash Flow | -23.38K | -35.92K | -53.70K | -67.66K | -64.68K |
| Operating Cash Flow | -23.38K | -35.92K | -53.70K | -67.66K | -64.68K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 27.00K | 28.83K | 0.00 | 0.00 | 182.43K |
NanoSphere Health Sciences Inc Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.02
Negative
0.02
Negative
Market Momentum
>-0.01
Negative
15.40
Positive
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NSHS, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 15.40 is Positive, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:NSHS.
NanoSphere Health Sciences Inc Peers Comparison
UnderperformOutperform
Sector (51)
TSE:NSHS
NanoSphere Health Sciences Inc
0.02
-0.02
-42.86%
TSE:WESA.X
Wesana Health Holdings Inc
0.01
0.00
0.00%
TSE:ABRT
Albert Labs International
0.01
0.00
0.00%
TSE:VXL
Vaxil Bio
0.23
-0.01
-6.25%
TSE:CHGX
ChitogenX
0.01
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.